Carisma Therapeutics Inc. (CARM)
0.23
0.01 (6.88%)
At close: Apr 25, 2025, 3:58 PM
0.22
-4.78%
After-hours: Apr 25, 2025, 06:02 PM EDT
Company Description
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors.
Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases.
Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc.
Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.
The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Carisma Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Steven Kelly |
Contact Details
Address: 3675 Market St. Philadelphia, Pennsylvania United States | |
| Website | https://carismatx.com |
Stock Details
| Ticker Symbol | CARM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001485003 |
| CUSIP Number | 14216R101 |
| ISIN Number | US14216R1014 |
| Employer ID | 26-2025616 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven Kelly | President, Chief Executive Officer & Director |
| Dr. Saar Gill M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Michael Klichinsky Ph.D., Pharm.D., PharmD | Co-Founder & Chief Scientific Officer |
| Natalie McAndrew | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | 8-K | Current Report |
| Mar 31, 2025 | S-8 | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Jan 30, 2025 | 4 | Filing |
| Jan 30, 2025 | 4 | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 02, 2025 | 3 | Filing |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 09, 2024 | 8-K | Current Report |